Skip to main content Skip to navigation
BV510 Mouse Anti-Human ROR1
Product Details
Down Arrow Up Arrow


BD OptiBuild™
Neurotrophic tyrosine kinase, receptor-related 1; NTRKR1
Human (Tested in Development)
Mouse BALB/c IgG2b, κ
Human ROR1 cDNA
Flow cytometry (Qualified)
0.2 mg/ml
AB_2741210
Aqueous buffered solution containing ≤0.09% sodium azide.
RUO


Preparation And Storage

Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated with BD Horizon BV510 under optimal conditions that minimize unconjugated dye and antibody.

Recommended Assay Procedures

For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime two or more BD Horizon Brilliant dyes (including BD OptiBuild Brilliant reagents) are used in the same experiment.  Fluorescent dye interactions may cause staining artifacts which may affect data interpretation.  The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions.  More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794).

Product Notices

  1. This antibody was developed for use in flow cytometry.
  2. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
  3. Researchers should determine the optimal concentration of this reagent for their individual applications.
  4. An isotype control should be used at the same concentration as the antibody of interest.
  5. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
  6. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
  7. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
  8. BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
  9. BD Horizon Brilliant Violet 510 is covered by one or more of the following US patents: 8,575,303; 8,354,239.
743013 Rev. 1
Antibody Details
Down Arrow Up Arrow
4A5

The 4A5 monoclonal antibody binds to the glycosylated type I membrane protein ROR1 (Receptor-tyrosine-kinase-like Orphan Receptor 1). The ROR1 and ROR2 related proteins are highly conserved evolutionarily and are primarily expressed during embryogenesis. ROR1 is not expressed on normal peripheral blood lymphocytes. ROR1 is similar to tropomyosin receptor kinase (Trk family) neurotropic receptors and shares a cysteine-rich domain with Frizzled receptors for Wnt-family signaling proteins, which are involved in the regulation of embryogenesis and carcinogenesis. Furthermore, there is mounting evidence that aberrant ROR1 expression contributes to human malignancy.

The antibody was conjugated to BD Horizon™ BV510 which is part of the BD Horizon Brilliant™ Violet family of dyes. With an Ex Max of 405-nm and Em Max at 510-nm, BD Horizon BV510 can be excited by the violet laser and detected in the BD Horizon V500 (525/50-nm) filter set. BD Horizon BV510 conjugates are useful for the detection of dim markers off the violet laser.

743013 Rev. 1
Format Details
Down Arrow Up Arrow
BV510
The BD Horizon Brilliant Violet™ 510 (BV510) Dye is part of the BD Horizon Brilliant Violet™ family of dyes. This polymer-technology based dye with an excitation maximum (Ex Max) at 327-nm / 405-nm and an emission maximum (Em Max) at 512-nm. BV510, driven by BD innovation, is designed to be excited by the violet laser (405-nm) and detected using an optical filter centered near 510-nm (e.g., a 525/50 bandpass filter). The dye can be excited by the UV (355-nm) laser resulting in cross-laser excitation and spillover. Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.
altImg
BV510
Violet 405 nm
327 nm, 405 nm
512 nm
743013 Rev.1
Citations & References
Down Arrow Up Arrow
View product citations for antibody "743013" on CiteAb

Development References (5)

  1. Broome HE, Rassenti LZ, Wang HY, Meyer LM, Kipps TJ. ROR1 is expressed on hematogones (non-neoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia. Leuk Res. 2011; 35(10):1390-1394. (Clone-specific: Flow cytometry). View Reference
  2. Cui B, Zhang S, Chen L, Yu J, et al. Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis. Cancer Res. 2013; 73(12):3649-3660. (Biology). View Reference
  3. Fukuda T, Chen L, Endo T, et al. Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc Natl Acad Sci U S A. 2008; 105(8):3047. (Immunogen: Flow cytometry). View Reference
  4. Zhang S, Chen L, Cui B, et al. ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth. PLoS ONE. 7(3)(Clone-specific: Immunohistochemistry). View Reference
  5. Zhang S, Chen L, Wang-Rodriguez J, et al. The onco-embryonic antigen ROR1 is expressed by a variety of human cancers. Am J Pathol. 2012; 181(6):1903-1910. (Clone-specific: Flow cytometry, Immunocytochemistry (cytospins), Immunohistochemistry, Immunoprecipitation). View Reference
View All (5) View Less
743013 Rev. 1

Please refer to Support Documents for Quality Certificates


Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.